FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation.
J
J
Aalbers
A
A
Bryer
E
E
Klug
D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D001562:Benzimidazoles / Q000627:therapeutic use*; D000069604:Dabigatran; D017277:Drug Approval; D019317:Evidence-Based Medicine; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use*; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D014481:United States
D000925:Anticoagulants; D001562:Benzimidazoles; D011725:Pyridines; D000069604:Dabigatran